Упрощенная HTML-версия
134
89.
Assessing symptom distress in cancer: The M. D. Anderson Symptom Inven-
tory / C. S. Cleeland [et al.] // Cancer. – 2000. – Vol. 89, № 7. – P. 1634-
1646.
90.
Assessment of drug-induced hepatotoxicity in clinical practice: a challenge
for gastroenterologist / R. J. Andrade [et al.] // World J. Gastroenterol. –
2007. – Vol. 13, № 3. – Р. 329-340.
91.
Assessment of pain / H. Breivik [et al.] // Br. J. Anaesth. – 2008. – Vol. 101,
№ 1. – P. 17-24.
92.
Attenuation of doxorubicin-induced cardiomyopathy by endothelin-
converting enzyme-1 ablation through prevention of mitochondrial biogenesis
impairment / K. Miyagawa [et al.] // Hypertension. – 2010. – Vol. 55, № 3. –
P. 738-746.
93.
Bakris G. Microalbuminuria – dowe need to screen everyone? / G. Bacris,
M.R. Weir // Электронныйресурс -2010.- Режим доступа:
www/medscape.com/viewarticle/733116.
94.
Berthiame J. M. Adriamicin-induced oxidative mitochondrial cardiotoxicity /
J. M. Berthiame, K. B. Wallace // Cell Biol. Toxicol. – 2007. – Vol. 23, № 1.
– P. 15-25.
95.
Biochemical markers for prediction of chemotherapy-induced cardiotoxicity:
systematic review of the literature and recommendations for use / A. Dolci [et
al.] //
– 2006. – Vol. 7, № 9. – P. 604-611.
96.
BNP cannot replace gated equilibrium radionucleide ventriculography in
monitoring of antrcycline-induced cardiotoxicity / T. W. Vogelsaug [et al.] //
Int J Cardiol. – 2008. – Vol. 124, № 2. – P. 193-197.
97.
Boogs W. Cardiac Echo, Enzymes Predict Cardiopathy after Breast cancer
chemo [Электронныйресурс] / W. Boogs // Am J Cardiol.-2011.-
98.
Bos J. L. ras oncogenes in human cancer: a review / J. L. Bos // Cancer Res. –
1989. – Vol. 49, № 17. – Р. 4682-4689.